CytoMed Therapeutics (GDTC) Assets (2021 - 2025)
CytoMed Therapeutics (GDTC) posted Assets of $6.2 million for Q4 2025, down 26.28% sequentially from $8.4 million in Q2 2025, and down 18.6% YoY from $7.6 million in Q4 2024.
CytoMed Therapeutics (GDTC) Assets (2021 - 2025) Analysis & Trends
CytoMed Therapeutics has reported Assets for 5 years, with the latest figure at $6.2 million in Q4 2025.
- Quarterly Assets fell 18.6% year-over-year to $6.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $6.2 million (down 18.6% YoY) and the FY2025 annual result came in at $6.2 million, down 17.61% from the prior year.
- Assets declined to $6.2 million in Q4 2025 per GDTC's latest filing, from $8.4 million in the prior quarter.
- Over five years, Assets peaked at $13.9 million in Q2 2023 and troughed at $3.8 million in Q4 2022.
- A 5-year average of $8.0 million and a median of $8.0 million in 2025 frame the typical range for Assets.
- The sharpest annual moves came in 2023 and 2025: Assets jumped 143.24% in 2023, then retreated 23.4% in 2025.
- Over 5 years, Assets stood at $4.5 million in 2021, then declined by 15.97% to $3.8 million in 2022, then surged by 143.24% to $9.2 million in 2023, then fell by 17.39% to $7.6 million in 2024, then declined by 18.6% to $6.2 million in 2025.
- According to Business Quant data, Assets over the past three periods registered $6.2 million, $8.4 million, and $7.6 million for Q4 2025, Q2 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 10.03 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 10.96 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 9.18 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 5.56 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 25.60 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 2.10 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.82 Bn |
| 10 | CytoMed Therapeutics | 10.72 Mn | 9.11 Mn | - | 6.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 6.16 Mn |
| Jun 30, 2025 | 8.36 Mn |
| Dec 31, 2024 | 7.57 Mn |
| Jun 30, 2024 | 10.91 Mn |
| Dec 31, 2023 | 9.16 Mn |
| Jun 30, 2023 | 13.91 Mn |
| Dec 31, 2022 | 3.77 Mn |
| Dec 31, 2021 | 4.48 Mn |